John Furey - Spark Therapeutics COO
COO
Mr. John P. Furey is no longer Chief Operating Officer of the Company effective January 1, 2019. He was Senior Vice President and Head of Global Operations of Baxalta Incorporated beginning upon Baxaltas separation from Baxter International Inc. in July 2015 until July 2016. Mr. Furey previously served as Head of Global Operations for Baxter International Inc. from October 2014 to July 2015 and as Global Franchise Head, Vaccines from February 2013 to September 2015. Prior to Baxter International Inc. Mr. Furey served as General Manager for Vaccines in China for Pfizer from April 2011 to January 2013. Prior to that, Mr. Furey spent 20 years with Wyeth and Pfizer, holding roles of increasing responsibility within the biotech and vaccines divisions, and various leadership roles in commercial, product supply and manufacturing operations. Early in his career he was an engineering manager at Analog Devices and served as a Scientific Officer with Irelands National Scientific Agency since 2016.
Age | 52 |
Tenure | 8 years |
Professional Marks | MBA |
Phone | 888 772-7560 |
Web | www.sparktx.com |
Spark Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.107) % which means that it has lost $0.107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1515) %, meaning that it created substantial loss on money invested by shareholders. Spark Therapeutics' management efficiency ratios could be used to measure how well Spark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 138.01 M in liabilities with Debt to Equity (D/E) ratio of 34.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has a current ratio of 5.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Spark Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Spark Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spark Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spark to invest in growth at high rates of return. When we think about Spark Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 2 records | COO Age | ||
Matthew Urmanski | WPP PLC ADR | 41 | |
Andrew Scott | WPP PLC ADR | 56 |
Management Performance
Return On Equity | -0.15 | |||
Return On Asset | -0.11 |
Spark Therapeutics Leadership Team
Elected by the shareholders, the Spark Therapeutics' board of directors comprises two types of representatives: Spark Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spark. The board's role is to monitor Spark Therapeutics' management team and ensure that shareholders' interests are well served. Spark Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spark Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Romuald Corbau, Translational Research Lead | ||
Carol GrevePhilips, Head of Business Development and Strategy | ||
Robert Perez, Director | ||
Lars Ekman, Independent Director | ||
Jennifer Wellman, Co-Founder and Head of Regulatory Strategy | ||
Fraser Wright, Co-Founder and CTO | ||
Morgan Molloy, Head of U.S. Commercial | ||
Lorris Betz, Director | ||
Joseph Barge, General Counsel and Head of Business Administration | ||
Katherine High, President Chief Scientific Officer, Director | ||
Elliot Sigal, Independent Director | ||
John Furey, COO | ||
Vincent Milano, Independent Director | ||
Lota Zoth, Director | ||
Rogerio Coelho, Chief Commercial Officer | ||
Elliott Sigal, Independent Director | ||
Guang Qu, Head of Process Development | ||
Daniel Takefman, Head of Regulatory Affairs | ||
Stephen Webster, CFO | ||
Rogerio Vivaldi, Chief Commercial Officer | ||
Diane Blumenthal, Head of Technical Operations | ||
Jeffrey Marrazzo, CEO, Co-Founder, Director | ||
Daniel Faga, Chief Business Officer | ||
Anand Mehra, Independent Director | ||
Linda Hearne, Financial Operations and Analysis Lead | ||
Paul Gil, Regulatory CMC and Quality Assurance Lead | ||
Charles Sigal, Independent Director | ||
Federico Mingozzi, Chief Scientific Officer | ||
Steven Altschuler, Chairman of the Board | ||
Lisa Dalton, Head - Human Resources |
Spark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spark Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.15 | |||
Return On Asset | -0.11 | |||
Profit Margin | (0.0009) % | |||
Current Valuation | 3.97 B | |||
Shares Outstanding | 38.49 M | |||
Shares Owned By Insiders | 7.45 % | |||
Shares Owned By Institutions | 92.25 % | |||
Number Of Shares Shorted | 3.47 M | |||
Price To Earning | (13.29) X | |||
Price To Book | 10.71 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Spark Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Spark Therapeutics' short interest history, or implied volatility extrapolated from Spark Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Spark Stock
If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |